Stellate Ganglion Block in the Treatment of Posttraumatic Stress Disorder
Key facts
- Who runs it
- The Royal's Institute of Mental Health Research
- Where
- Canada1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Enrolling by invitation
- Phase
- Phase 3
- People taking part
- 54 people, planned
- Started
- 30 Mar 2024
- Expected to end
- 30 Jan 2027
- Type of study
- Interventional, 2 groups
- Treatments tested
- 5 mL of 0.5% preservative-free bupivacaine
- Record updated
- 25 July 2025
Who can take part
- Age
- 18 years to 69 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (27)Hide the full registry criteria
Who can take part
- Diagnosis of PTSD according to DSM-5 criteria with prominent and persistent cluster E hyperarousal symptoms
- Age 18-69 years
- Under care of a mental health clinician
- Not benefited from adequate trials of pharmacological or psychological evidence-based treatment and/or a preference and consent for a trial of SGB
Who cannot take part
- Diagnosis of bipolar or psychotic disorder
- History of bleeding disorder (based on chart and verbal report from patient)
- Infection, mass or anatomic abnormalities at target injection site
- Myocardial infarction within 6 months of procedure (based on chart and verbal report from patient)
- Pathologic bradycardia or irregularities of heart rate or rhythm (based on chart and verbal report from patient)
- History of glaucoma (based on chart and verbal report from patient)
- Uncontrolled seizure disorder (based on chart and verbal report from patient)
- Known history of allergy to local anesthetics (based on chart and verbal report from patient)
- Active systemic infection (based on chart and verbal report from patient)
- Any other condition that in the opinion of the investigator could create a hazard to the participant's safety, endanger the study procedures, or interfere with the interpretation of study results
- Assessed with high risk for suicide in the last 30 days (per patient's treating clinician at OSI clinic)
- Moderate to severe substance use within the last 30 days (based on chart and verbal report from patient)
- In process of disability assessment or legal action
- Moderate or severe TBI (based on chart and verbal report from patient)
- Pregnancy or breastfeeding
- Current anticoagulant use (eligible if can be held before the procedure)
- Symptomatic hypotension (BP<90/60 + clinical symptoms of hypotension)
- Phrenic or laryngeal nerve palsy (based on chart and verbal report from patient)
- Severe COPD (based on chart and verbal report from patient)
- Pneumothorax (based on chart and verbal report from patient)
- Contralateral pneumonectomy or non-functional lung (based on chart and verbal report from patient)
- Patient refusal/inability to tolerate procedure/positioning
- Contraindication to MR imaging
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
- Ptsd
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The most common treatment for Posttraumatic Stress Disorder (PTSD) is trauma-focused therapy and/or prescription of medication(s). However, these treatments may not directly reduce symptoms associated with PTSD, making it difficult for patients to be treated for this condition and recover. Stellate ganglion block (SGB) is a medical procedure that involves injection of a local anesthetic (a medication that causes reduced sensation/feeling in a given area) around the stellate ganglion, which is a collection of nerves near the base of the neck. This procedure causes a short-lived, temporary shutdown of nerve signals (up to 5-7 hours) and is commonly performed in Canada for certain pain and medical conditions. In the last decade, several studies, including those involving members of military groups, have shown that SGB can result in a rapid and sustained drop in symptoms related to PTSD such as overwhelming anxiety, increased irritability, heightened alertness, and exaggerated startle. Considering these results and the known safety of this procedure (as demonstrated by previous research and use in other illnesses), SGB has been increasingly used to treat PTSD among veterans in the United States but has not yet been evaluated in Canada. More research is thereby needed to use SBG as a method of PTSD treatment in Canada, and to better understand how it works to reduce symptoms associated with this condition. Health Canada, the organization which oversees clinical trials such as this one, has not approved the use of the SGB procedure for PTSD in the general population, however Health Canada has allowed the use of SGB in this study to better understand how it works and how it may be used in the future to treat PTSD-related symptoms in those who feel that common treatments are not effective.
The 2 groups in the trial
- Single SGBOther group
This arm will receive a single 5 mL dose of 0.5% preservative-free bupivacaine.
Treatment: 5 mL of 0.5% preservative-free bupivacaine
- Repeated SGBOther group
This arm will receive two 5 mL doses of 0.5% preservative-free bupivacaine.
Treatment: 5 mL of 0.5% preservative-free bupivacaine
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Stellate Ganglion Block in the Treatment of Posttraumatic Stress Disorder: Outcome Evaluation, Mechanism of Action, and Integration in Care - A Phase III Randomized Controlled Trial
- Criteria questions
- Built from NCT05427500, who can take part
- Record updated
- 25 July 2025